Pluristem Therapeutics (PSTI) Leaps on FDA Designation

Pluristem Therapeutics Inc.

shares rose 14.1% to $1.13 after the company reported that the U.S. FDA has granted Orphan Drug Designation to Pluristem's PLX-PAD cells. Share volume was 446.000, compared to an all-day average of 33,000